Jamie Brett | Authors

Articles

CDK 4/6 Inhibitors Show Efficacy in HR+ MBC With ESR1 Mutations

April 27, 2022

Jamie Brett, resident in internal medicine at Massachusetts General Hospital, discusses the effectiveness of CDK4/6 for patients with hormone receptor-positive metastatic breast cancer (MBC) with ESR1 mutations and fusions.